Artiva Biotherapeutics Inc. shares pared initial gains to end flat in the company’s trading debut after raising $167 million in an expanded initial public offering. Shares of the clinical stage biotechnology company, backed by South Korea’s Green Cross Corp., traded as high as $16 each before retreating to their $12 IPO price on Friday in New York.
